ROS1 and adenocarcinoma: The median age of ROS1-fusion positive patients was younger than ROS1-fusion negative cases in the limited subsets (55 vs 58 years), suggesting that ROS1 rearrangement in resected stage IIIA-N2 NSCLC occurred mainly in certain subgroups, such as the young and those with adenocarcinoma.